BioXcel Therapeutics (BTAI) Receivables (2022 - 2026)

BioXcel Therapeutics' Receivables history runs 5 years deep, the most recent figure standing at $216000.0 for Q1 2026.

• In Q1 2026, Receivables changed N/A year-over-year to $216000.0; the TTM figure through Mar 2026 stood at $216000.0 (changed N/A YoY), while the FY2025 annual figure was $233000.0, up 77.86% from the prior year.
• Receivables was $216000.0 for Q1 2026 at BioXcel Therapeutics, down from $233000.0 in the prior quarter.
• In the past five years, Receivables ranged from a high of $812000.0 in Q2 2024 to a low of $3000.0 in Q3 2024.
• Historically, Receivables has averaged $296500.0 across 5 years, with a median of $240500.0 in 2022.
• Biggest YoY gain for Receivables was 88.4% in 2024; the steepest drop was 99.59% in 2024.
• A 5-year view of Receivables shows it stood at $248000.0 in 2022, then slumped by 71.37% to $71000.0 in 2023, then soared by 84.51% to $131000.0 in 2024, then surged by 77.86% to $233000.0 in 2025, then fell by 7.3% to $216000.0 in 2026.
• The last three Receivables figures came in at $216000.0 (Q1 2026), $233000.0 (Q4 2025), and $17000.0 (Q2 2025), per Business Quant data.